abstract |
The present invention relates to the new use of an already known biomolecule methyl-β-orcinol carboxylate of formula 1 isolated from a lichen ( Everniastrum cirrhatum ), for treating pathogenic fungal infections of humans that are resistant to polyene and azole antibiotics such as amphotericin B, nystatin, clotrimazole etc. |